Exagen and GSK partner for 4th straight year, driving greater awareness of challenges facing lupus diagnosis and management
November 16 2020 - 8:25AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it has extended its collaboration agreement
with GlaxoSmithKline plc (GSK), one of the world’s leading
healthcare companies, to raise awareness of the importance of
timely diagnosis of systemic lupus erythematosus (SLE), the most
common and severe form of lupus. At the center of the program are
the proprietary AVISE® laboratory tests, which can facilitate early
diagnosis and management of SLE, a complex, incurable autoimmune
disease. The details of the agreement are confidential.
This extension follows a similar one-year extension that Exagen
and GSK entered into last year, and will continue to support the
shared goal of helping SLE patients shorten the time to their
diagnosis, which is nearly six years on average, and to facilitate
improved patient outcomes.
Ron Rocca, President and CEO of Exagen shared, “We’re pleased to
continue working with GSK, which demonstrates our ability to
collaborate with major pharmaceutical companies in a shared
commitment to improve patients’ lives. Having access to advanced
test result data such as the AVISE® tests can support diagnosis,
prognosis, and monitoring of challenging conditions like SLE.”
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand. Several of these products are based on our
proprietary Cell-Bound Complement Activation Products, or CB-CAPs,
technology. CB-CAPs assess the activation of the complement system,
a biological pathway implicated in systemic lupus erythematosus, or
SLE. Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis, or RA. Exagen’s model of
integrating testing products and therapeutics positions Exagen to
offer targeted solutions to rheumatologists and, ultimately, better
serve patients. For more information, please visit
www.Exagen.com.
About GSK
GSK – a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com/about-us.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding
the expected benefits or results of Exagen’s collaboration with
GSK, and the performance the AVISE® laboratory tests and benefits
of the test results data obtained therefrom. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: the COVID-19 pandemic may
continue to adversely affect our business, financial condition and
results of operations, including as a result of shutdowns of our
facilities and operations as well as those of our suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for our tests, our sales and
commercialization activities and our ability to receive specimens
and perform or deliver the results from our tests, delays in
reimbursement and coverage decisions from Medicare and third-party
payors and in interactions with regulatory authorities, and delays
in ongoing and planned clinical trials involving our tests; the
company’s commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; the company’s ability to
successfully execute on its Dx/Rx strategy, including its promotion
efforts for SIMPONI®; third party payers not providing coverage and
adequate reimbursement for the company’s testing products or
promoted therapeutics; the company’s ability to obtain and maintain
intellectual property protection for its testing products;
regulatory developments affecting the company’s business; and other
risks described in the company’s prior press releases and the
Company’s filings with the Securities and Exchange Commission
(SEC), including under the heading “Risk Factors” in the company’s
Annual Report on Form 10-K and any subsequent filings with the SEC.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com 646.677.1838
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024